{"id":"adapalene-gel-0-3","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Erythema"},{"rate":"10-20","effect":"Scaling/peeling"},{"rate":"5-15","effect":"Dryness"},{"rate":"5-10","effect":"Pruritus"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":{"setId":"c448eab6-c054-4c8b-9319-556b7e1be3cf","title":"ADAPALENE GEL USP, 0.3% GEL [BRYANT RANCH PREPACK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adapalene selectively activates retinoic acid receptor gamma (RARγ) and other RAR subtypes, promoting keratinocyte differentiation and reducing sebum production. It decreases comedone formation and has anti-inflammatory properties, making it effective for treating acne by normalizing follicular epithelial desquamation and reducing bacterial colonization.","oneSentence":"Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:56.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Photoaging and fine wrinkles (off-label use in some regions)"}]},"trialDetails":[{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT06336603","phase":"PHASE4","title":"A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2023-11-15","conditions":"Acne Vulgaris","enrollment":20},{"nctId":"NCT02899000","phase":"PHASE4","title":"A Treatment for Severe Inflammatory Acne Subjects","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2016-07-29","conditions":"Acne Vulgaris","enrollment":186},{"nctId":"NCT02735421","phase":"PHASE4","title":"Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2016-05-13","conditions":"Acne Vulgaris, Atrophic Acne Scars","enrollment":67},{"nctId":"NCT00671749","phase":"PHASE4","title":"Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-12","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT00647556","phase":"PHASE3","title":"Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-04","conditions":"Photoaging","enrollment":30},{"nctId":"NCT05096312","phase":"PHASE4","title":"Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients","status":"COMPLETED","sponsor":"East Avenue Medical Center, Philippines","startDate":"2018-12-21","conditions":"Acne Vulgaris","enrollment":23},{"nctId":"NCT00660985","phase":"PHASE4","title":"Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-05","conditions":"Acne Vulgaris","enrollment":51},{"nctId":"NCT01213199","phase":"PHASE2","title":"Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-03","conditions":"Acne Scars","enrollment":20},{"nctId":"NCT02932267","phase":"PHASE3","title":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-02-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT02651220","phase":"PHASE3","title":"Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-11","conditions":"Acne","enrollment":1001},{"nctId":"NCT03650361","phase":"PHASE3","title":"Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Aleor Dermaceuticals Limited","startDate":"2018-09-17","conditions":"Acne Vulgaris","enrollment":755},{"nctId":"NCT03457636","phase":"PHASE4","title":"The Use of Oracea and Epiduo Forte in Severe Acne Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2018-03-19","conditions":"Acne","enrollment":22},{"nctId":"NCT02411942","phase":"PHASE1","title":"Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-08","conditions":"Acne Vulgaris","enrollment":753},{"nctId":"NCT02709902","phase":"PHASE1","title":"Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09","conditions":"Acne Vulgaris","enrollment":460},{"nctId":"NCT01406080","phase":"PHASE3","title":"A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging","status":"COMPLETED","sponsor":"Galderma Brasil Ltda.","startDate":"2013-01","conditions":"Photoaging, Photodamage","enrollment":128},{"nctId":"NCT01425320","phase":"PHASE1","title":"Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-01","conditions":"Acne Vulgaris","enrollment":""},{"nctId":"NCT00829049","phase":"PHASE4","title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-10","conditions":"Acne Vulgaris","enrollment":165},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT01485367","phase":"PHASE2","title":"A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura","status":"UNKNOWN","sponsor":"Multispecialty Aesthetic Clinical Research Organization","startDate":"2011-12","conditions":"Senile Purpura","enrollment":20},{"nctId":"NCT00714714","phase":"PHASE4","title":"Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-01","conditions":"Acne Vulgaris","enrollment":25},{"nctId":"NCT01095640","phase":"NA","title":"Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2009-03","conditions":"Acne Vulgaris","enrollment":1159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Differin® 0.3% Gel","Differin® Gel, 0.3%"],"phase":"marketed","status":"active","brandName":"adapalene gel, 0.3%","genericName":"adapalene gel, 0.3%","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation. Used for Acne vulgaris, Photoaging and fine wrinkles (off-label use in some regions).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}